Clinical Trial Search

Primary: Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST — 1; 0; 0; 0 participants

Primary: Percentage of Participants in Objective Response at 6 Months — 0.0; 0.0; 0.0; 6.7 percentage of participants

Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…

Primary: Overall Objective Response — 1; 21; 26 participants

Primary: Percentage of Participants With Progression-Free Survival (PFS) at 12 Weeks — 27.3; 12.5; 25.4; 50.0 percentage of participants

Primary: Antitumor Activity as Assessed by Number of Patients Showing an Objective Tumor Response — 0 participants

Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months

Primary: Overall Objective Response — 5; 22; 8 participants

Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants

Primary: Disease Control Rate — 13; 2; 3 Participants

Primary: Response Rate (CR + PR) Assessed by RECIST 1.1 (Phase II) — 4; 1; 5; 0 participants

Primary: Objective Response (Complete Response (CR)+Partial Response (PR) of Cabozantinib in Patients With Soft Tissue Sarcomas — 11.1 percentage of particpants

Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient

Primary: Part I: Objective Response Rate (ORR) of Single-agent Cediranib in Participants With Advanced Alveolar Soft Part Sarcoma (ASPS) — 0; 0; 0; 1 Participants

Primary: Pathologic Response Rate, Defined as the Percentage of Participants With Greater Than or Equal to 95% Necrosis. — 20 % of participants

Primary: Overall Response Rate — 0; 2 Participants

Primary: Progression-free Survival (PFS) — 7.0; 20.0 weeks — p=<0.001

Primary: Maximum Tolerated Dose of ABI-009 — 100 mg/m^2

Primary: Response Rate (Per RECIST 1.1) — 1 Participants

Primary: Number of Participants Who Achieved a Confirmed Response — 2; 6; 1; 2 Participants

Primary: Response Rate: Number of Participants With Objective Tumor Response — 12; 14; 20 Participants

Primary: Objective Response Rate — 7; 2; 7 Participants

Primary: Number of Participants With Overall Response (OR) — 1 participants

Primary: Response Rate for Amrubicin in Patients With Metastatic or Advanced Sarcoma as First Line Therapy. — 13 percentage of pt with a partial response

Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants

Primary: 6-month Progression-free Survival Rate (PFS) — 12 participants

Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants

Primary: Best Overall Response Rates by Week 16 (ITT) — 0; 0; 0; 0 percentage of participants — p=0.1

Primary: Progression-free Survival (PFS). Cohort A and Cohort B — 1.87; 2.07; 3.6; 1.7 months

Primary: Progression-free Survival — 1.8; 3.7 months